proteosome-adjuvanted trivalent inactivated influenza vaccine

A proteosome-adjuvanted trivalent inactivated influenza vaccine is a combination product consisting of three inactivated influenza virus antigens (typically two influenza A subtypes and one influenza B lineage) formulated with a proteosome-based adjuvant. Proteosome adjuvants are derived from bacterial outer membrane proteins, which function by enhancing the immunogenicity of co-formulated antigens through improved antigen presentation and stimulation of innate immune pathways. This vaccine is designed to induce strong, broad and long-lasting immune responses, particularly in populations such as older adults who may have weaker responses to unadjuvanted traditional influenza vaccines. The primary indication is for the prevention of seasonal influenza. While MF59 (squalene-based oil-in-water emulsion) is the only adjuvant in currently US-licensed adjuvanted trivalent vaccines as of 2025[1][2][4], proteosome-adjuvanted influenza vaccines have been investigated in clinical trials and may be available in some regions or in development.

Other names

Intranasal Proteosome-Adjuvanted Trivalent Influenza VaccineProtesomal Vaccineprotesomal vaccine-Hvivo-Influenza